American Cyanamid Company

William J McGahren

George A Ellestad

Martin J Weiss

Robert E Schaub

Martin L Sassiver

Middleton Brawner Floyd

Philip R Hamann

Janis Upeslacis

Lois M Hinman

Middleton B Floyd, Jr

Donald B Borders

Amedeo A Fantini

Homer D Tresner

A process is described for producing substituted disulfide analogs of the family of antibacterial and antitumor agents known collectively as the LL-E33288 complex.

Antitumor and antibacterial substituted disulfide derivatives prepared

This disclosure describes a method for constructing targeting agent drug conjugates from the family of methyltrithio antibacterial and antitumor agents.

Process for preparing targeted forms of methyltrithio antitumor agents

This disclosure describes disulfide analogs of the family of antibacterial and antitumor agents known collectively as the LL-E33288 complex.

This disclosure describes a method for constructing carrier-drug conjugates from the family of methyltrithio antibacterial and antitumor agents.

Targeted forms of methyltrithio antitumor agents

Processes for producing antibacterial and antitumor agents designated LL-E33288.epsilon.I and LL-E33288.epsilon.-Br using triphenylphosphine or a sulfhydryl-containing reagent are disclosed. Processes for producing reductively aromatized derivatives of other antibiotics are also disclosed.

Process for producing the antibiotic and antitumor agents LL-E33288.epsilon

Processes for producing antibacterial and antitumor agents designated LL-E33288.epsilon.-I and LL-E33288.epsilon.-Br using triphenylphosphine at ice bath temperature are disclosed. Novel intermediates prepared in the processes are also disclosed.

Intermediate and process for producing the antibacterial and antitumor

Antibacterial and antitumor agents designated LL-E333288.epsilon.-I and LL-E33288.epsilon.-Br and their production by strains of Micromonospora echinospora ssp. calichensis designated NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Antibacterial and antitumor agents LL-E33288EPSILON-I and

This disclosure describes three new antibiotics designated BM782.alpha.1, BM782.alpha.2, and BM782.alpha.1a which are produced in a microbiological fermentation under controlled conditions using a new strain of an undetermined species of the genus Nocardia or mutants thereof. These new antibacterial agents are active against Mycobacterium tuberculosis as well as both gram-positive and gram-negative microorganisms and thus are useful for inhibiting the growth of such bacteria and bacilli wherever they may be found.

Antibacterial antibiotic BM782

This disclosure describes certain hydroxy substituted 15-deoxy-5-cis-prostenoic acids and esters useful as hypotensive agents, anti-ulcer agents, bronchodilators, anti-microbial agents, anticonvulsants, or as intermediates.

Novel hydroxy substituted 15-deoxy-5-cis-prostenoic acids and esters

Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters

This disclosure describes certain 15-deoxy prostanoic acid derivatives having a hydroxy group further along in the beta-chain, useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

Growing community of inventors

Demarest, NJ, United States of America

William J McGahren